IDH2 and cholangiocarcinoma: Using multiple in vitro and preclinical animal models of glioma and cholangiocarcinoma, Wang et al. demonstrated that the activity of PARP inhibitor veliparib had been synergistically enhanced by concurrent, localized radiation therapy, while the same radiosensitizing effect was not observed in IDH-wt xenografts [56].